When profiling the kinase substrates in BRAF wild-type melanoma cell line (MelJD), we observed that kinase inhibition upon in-vitro vemurafenib treatment occurred to a similar degree as in the vemurafenib-sensitive cell line (MM200) harboring BRAF(V600E). Here, BRAF is linked to melanoma.